OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2184-2197
Open Access | Times Cited: 13
Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2184-2197
Open Access | Times Cited: 13
Showing 13 citing articles:
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 16
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 16
Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
Pia Gattinger, Liubov I. Kozlovskaya, Alexander S. Lunin, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Pia Gattinger, Liubov I. Kozlovskaya, Alexander S. Lunin, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
EBioMedicine (2023) Vol. 92, pp. 104574-104574
Open Access | Times Cited: 13
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
EBioMedicine (2023) Vol. 92, pp. 104574-104574
Open Access | Times Cited: 13
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 10
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 10
CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2
Sedthawut Laotee, Methawee Duangkaew, Araya Jivapetthai, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288486-e0288486
Open Access | Times Cited: 8
Sedthawut Laotee, Methawee Duangkaew, Araya Jivapetthai, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288486-e0288486
Open Access | Times Cited: 8
Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with Chlamydia muridarum
Sukumar Pal, Anatoli Slepenkin, Jiin Felgner, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 863-863
Open Access | Times Cited: 5
Sukumar Pal, Anatoli Slepenkin, Jiin Felgner, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 863-863
Open Access | Times Cited: 5
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
David G. Alleva, Eline A. Feitsma, Yester F. Janssen, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
David G. Alleva, Eline A. Feitsma, Yester F. Janssen, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Subunit protein-based vaccines
Vasso Apostolopoulos, Vivek P. Chavda
Elsevier eBooks (2024), pp. 51-62
Closed Access | Times Cited: 1
Vasso Apostolopoulos, Vivek P. Chavda
Elsevier eBooks (2024), pp. 51-62
Closed Access | Times Cited: 1
Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity
Guo-Qing Zou, Ke Li, Cheng Yan, et al.
Vaccine (2024) Vol. 42, Iss. 21, pp. 126145-126145
Closed Access | Times Cited: 1
Guo-Qing Zou, Ke Li, Cheng Yan, et al.
Vaccine (2024) Vol. 42, Iss. 21, pp. 126145-126145
Closed Access | Times Cited: 1
Integrating 16S rRNA profiling and in-silico analysis for an epitope-based vaccine strategy against Achromobacter xylosoxidans infection
Muhammad Naveed, Ali Hassan, Tariq Aziz, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112287-112287
Closed Access
Muhammad Naveed, Ali Hassan, Tariq Aziz, et al.
International Immunopharmacology (2024) Vol. 135, pp. 112287-112287
Closed Access
The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2
Kanwal Khalid, Hui Xuan Lim, Jung Shan Hwang, et al.
The AAPS Journal (2024) Vol. 26, Iss. 5
Closed Access
Kanwal Khalid, Hui Xuan Lim, Jung Shan Hwang, et al.
The AAPS Journal (2024) Vol. 26, Iss. 5
Closed Access
Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids
Ke Li, Xing Hu, Xinyi Tu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Ke Li, Xing Hu, Xinyi Tu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 <sup>th</sup> Dose Booster
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
(2023)
Closed Access | Times Cited: 1
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
(2023)
Closed Access | Times Cited: 1
